Home › Decisions › PFE 2026-02-24

PFE FDA decision — Feb 24, 2026

✓ APPROVED

Pfizer Inc. — BRAFTOVI (encorafenib) in combination with c · BRAF V600E-Mutant Metastatic Colorectal Cancer.

Run-up into the decision (T-120 → T+5)

Daily close, T-120 (9/9/25) through T+5. Run-up high $27.73 on 2/12/26, low $23.6 on 10/2/25 (T-120 to T-1). FDA decision 2/24/26. Historical price action, not a forecast.

Key facts

FDA decision date2026-02-24

OutcomeApproved

Drug / candidateBRAFTOVI (encorafenib) in combination with c

CompanyPfizer Inc.

120-day run-up (T-120→T-1)+8.3%